Ludlow Research Upgrades FITX Based on Sales Revenue
(NEW YORK)--Ludlow Capital, an equity research firm based out of New York City, issued research opinion on Creative Edge Nutrition. (OTC:FITX), with a valuation price target of $0.02 to $0.03 per share.
- Acquisition Increases Value - ROGUE Supplements now being sold, Sales - Quarter to Show Sharp Increase in Sales and Earnings - Real Float Remains the Same at 10 Million (confirmed)
Based on the fact that FITX is currently generating sales revenue from their recently acquire ROGUE supplement line, and the point that the company will show real earnings in this quarterly report, Ludlow has issued a $0.02 to $0.03 target short-term on the company common stock.